Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLACE-adults: PK/PD of Crizanlizumab in Sickle Cell Disease
NCT03264989Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of crizanlizumab in sickle cell disease (SCD), sponsored by Novartis. Started Dec 2017; status: completed.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03264989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264989.